文献速递炎症性肠病

药物基因组学的祖先多样性影响西班牙裔/拉丁裔炎症性肠病患者的治疗

Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-23

多中心回顾性队列研究纳入2225例西班牙裔参与者,分析NUDT15、TPMT和HLA-DQA1∗05基因多态性频率及其对硫嘌呤相关白细胞减少和抗TNF免疫原性的影响,发现NUDT15∗4在美洲原住民等位基因中与白细胞减少相关,HLA-DQA1∗05与抗TNF免疫原性相关但rs2097432仅在欧洲等位基因中相关。

要点

  • 在美洲原住民/阿拉斯加原住民血统个体(包括西班牙裔)中,处方硫嘌呤前应进行NUDT15检测并成为标准临床实践。
  • rs2097432不应作为HLA-DQA1∗05检测的替代指标用于多样化人群。
  • 将祖先背景纳入个性化治疗对西班牙裔炎症性肠病患者重要。

核心结论

  • 在美洲原住民/阿拉斯加原住民血统个体(包括西班牙裔)中,处方硫嘌呤前应进行NUDT15检测并成为标准临床实践。
  • rs2097432不应作为HLA-DQA1∗05检测的替代指标用于多样化人群。
  • 将祖先背景纳入个性化治疗对西班牙裔炎症性肠病患者重要。

研究设计与样本

  • 多中心、回顾性队列研究,纳入2225例西班牙裔参与者。
  • 检测NUDT15、TPMT和HLA-DQA1∗05中影响药物反应的变异频率及其祖先起源(欧洲、非洲或美洲原住民)。
  • 在暴露患者中评估硫嘌呤和抗TNF药物相关骨髓抑制和免疫原性的发生率。

主要发现

  • NUDT15和TPMT变异罕见,但NUDT15 rs116855232仅在美洲原住民起源等位基因中常见。
  • 所有NUDT15变异等位基因均遗传自美洲原住民单倍型。
  • 在美洲原住民等位基因亚组中,NUDT15∗4(rs147390019)变异频率在白细胞减少患者中为23%,而在无白细胞减少患者中仅为3%。
  • HLA-DQA1∗05及其欧洲标签变异rs2097432在所有祖先起源等位基因中常见,并与抗TNF免疫原性相关。
  • rs2097432仅在欧洲等位基因亚组中与HLA-DQA1∗05相关。

临床怎么用

  • 作者建议:在美洲原住民/阿拉斯加原住民血统个体(包括西班牙裔)中,处方硫嘌呤前应进行NUDT15检测并成为标准临床实践。
  • 作者建议:rs2097432不应作为HLA-DQA1∗05检测的替代指标用于多样化人群。
  • 作者认为:将祖先背景纳入个性化治疗对西班牙裔炎症性肠病患者重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The prevalence of inflammatory bowel disease among Hispanic/Latine communities is increasing. Pharmacogenomic studies reveal genetic markers that influence treatment decisions. The aim of our study was to examine the frequency and impact of genetic polymorphisms on thiopurine-associated leukopenia (NUDT15, TPMT) and anti-tumor necrosis factor (TNF) immunogenicity (HLA-DQA1∗05) in a cohort of Hispanic patients of diverse ancestral backgrounds. METHODS: We performed a multicenter, retrospective cohort study comprising 2225 Hispanic participants. We measured the frequency of variation affecting drug response in NUDT15, TPMT, and HLA-DQA1∗05; their ancestral origin (European, African, or Amerindian); and the rate of development of myelosuppression and immunogenicity to thiopurines and anti-TNFs, in exposed patients. RESULTS: NUDT15 and TPMT variants were rare, except for rs116855232 in NUDT15, which was common only in alleles of Amerindian origin. All NUDT15 variant alleles were inherited on an Amerindian haplotype, and among the Amerindian allele subset, the variant frequency of NUDT15∗4 (rs147390019) was a remarkable 23% in patients with leukopenia but only 3% in patients without leukopenia. HLA-DQA1∗05 and its European tagging variant rs2097432 were common in alleles from all ancestral origins and demonstrated association with immunogenicity to anti-TNFs. However, rs2097432 was only correlated with HLA-DQA1∗05 in the European allele subset. CONCLUSIONS: These findings indicate that NUDT15 testing should become standard clinical practice before prescribing thiopurines in individuals with Amerindian/Alaska Native ancestry, including Hispanic individuals. Additionally, rs2097432 should not be used as a surrogate for HLA-DQA1∗05 testing for diverse populations. Ultimately, incorporating ancestry in personalized therapeutic approaches is important for treatment of Hispanic patients with inflammatory bowel disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ioannou S, Beecham A, Gomez L, et al. Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39181428. doi:10.1016/j.cgh.2024.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。